UPC: 023542600453
# WA0051

Product Is Available!


One capsule provides 1.5 billion live cells of L.
acidophilus, B. bifidum, and B. longum, the Friendly
Trio™. Unique human strains selected specifically to adapt
to the human intestinal tract. Acidophilus bacteria
predominantly colonize the upper to lower part of the
small intestine, while bifidum and longum colonize primarily
the lower part of the small intestine to the large
intestine. Combining these strains may help suppress harmful
bacteria and the substances they produce along the
entire intestinal tract.1-4 KYO-DOPHILUS is ideal both for
those who have been exposed to antibiotics and would
like to restore their intestinal flora, and also for those
who would simply like to assure a surplus of beneficial
bacteria in their intestinal tract. Friendly bacteria may
nutritionally assist in the body's normal response to
yeast.5 Guaranteed stability at room temperature. Does
not require refrigeration. SUGGESTED USE: Take one capsule
for adults (1/2 capsule for children under four) with a meal
twice daily. For infants, sprinkle 1/2 capsule in food or
juice. Supplement Facts Serving Size 1 capsule
Product Code: 600-44: 360 capsules 600-42: 180
capsules 600-45: 45 capsules 600-49: 90 capsules
Amount per capsule L. acidophilus, B. bifidum and B.
longum providing 1.5 billion live cells at the time of
consumption prior to expiration 350 mg† †Daily Value not
established OTHER INGREDIENTS: Gelatin, Vegetable Starch
Complex (potato starch and silica). Free of: preservatives,
sugar, sodium, milk, yeast, artificial colors and
flavors. Why Human Strains? It is important to be aware
that the human intestinal tract may be more sensitive to strains
introduced to it than those introduced to the intestinal tracts
of animals. What this means is that bacterial strains that are
effective in one species of animal are not necessarily effective
in another species. This is because the digestive tract varies
from species to species and bacteria have to have certain
characteristics in order to survive in the intestinal tract in
which they are dwelling. Specifically, bacterial strains
indigenous to humans are more likely to survive in the
intestinal tracts of humans than are non-human strains since
they are specifically adapted to grow in the intestinal tracts
of humans.1,2 They must be able to withstand stomach acid, in
order to make it to the intestinal tract. They must be able to
withstand intestinal fluids and they must be able to adhere to
the lining of the intestinal tract to exert their greatest
benefits. Bacteria derived from dairy or other sources are less
likely to remain in the intestinal tract of humans. They may
afford only temporary, if any, benefits. On the other hand,
human strains show better colonization and effectiveness. For
this reason, each of our probiotic formulas is formulated with
human strains. How Were the Human Strains Derived? The
bacteria strains used in WAKUNAGA'S PROBIOTICS were derived from
single strains of bacteria donated by Microbiology Professors
from the University of Tokyo and the Dokkyo Medical University
of Japan. Each strain was obtained from a healthy, living
subject in a one time collection. The bacteria of choice were,
isolated, identified, purified and mass produced after this
single collection. Bacteria were obtained about three decades
ago and have been naturally replicating in the laboratory every
since for mass production. They undergo numerous tests to assure
the bacteria are healthy and maintain their positive
characteristics. Consuming bacteria is safer than eating produce
from the grocery store, because consistent microscopic
investigation would be impossible for produce but is commonplace
where bacteria products are concerned. Why Take A
Probiotic? By providing large numbers of these friendly
bacteria to the intestinal tract they may increase the
population of these bacteria compared to other less desirable
strains. These strains may then competitively inhibit the growth
of undesirable strains and also inhibit the production of toxic
substances produced by less desirable strains.3 Further, studies
suggest that they may stimulate our immune system to suppress
the growth of pathogenic or undesired bacteria.4-6 Any
Clinical Studies for Safety or Effectiveness? A clinical
study of 180 patients from eight different medical facilities in
Japan noted significant improvement in patients with soft stools
or diarrhea from taking a probiotic product containing
Wakunaga's Lactobacillus acidophilus (L. acidophilus) and
Bifidobacterium bifidum (B. bifidum).7 Regarding constipation, a
clinical study of 39 patients showed improvement in 95% of the
subjects after taking a multistrain product including Wakunaga's
L. acidophilus and B. bifidum.4 Another clinical study using the
same product showed improvement in 58 of 64 subjects with
constipation.7 Abdominal distension improved in 63 of 66
subjects and frequency, hardness and odor improved. Clinical
studies conducted on nearly 300 subjects revealed no side
effects in subjects taking Wakunaga Probiotics.8,9 The
probiotic strains used by Wakunaga have no toxicity based on
basic toxicological and preclinical
studies. References Salminen, S. and Wright, A. V.
(1993) ed. Lactic Acid Bacteria. Marcel Dekker Inc., New York,
pp. 200-201. Golden, B.R. and Gorbach, S.L. Ch. 13.
Probiotics. The Scientific Basis (Fuller, R., ed.), Chapman &
Hall, London, 1992, pp. 367-368. Yamashita, M., Fujisaki,
M., Ohkushi, E., Kaihatsu, K. and Uchida, S. (1987) Ecological
study of effects of administration of three kinds of lactic acid
bacteria on suppression of intestinal decomposed substance.
Clinics and Microorganisms 13(b): 87. Honma, N., Ohtani, K.
and Kikuchi, H. (1987) On effects of lactic acid bacteria. Part
II. Clinical effects. New Medicines and Clinics 36(1): 75.
Honma, N. (1986) On effects of lactic acid bacteria. Part I.
Biological significance New Medicines and Clinics 35(12):
2687-2695. Honma, N. (1974) Intestinal bacteria flora of
infants and infection protection. Pediatric Clinics 27(11): 20.
In-House Clinical Study Conducted on 180 Patients from 8
Different Medical Facilities (Kobe University and associated
hospitals.) Willard, T. (1989) Occurrence of diarrhea with
the use of Kyo-Dophilus. Chiron Consultants Inc. Calgary,
Canada. Willard, T. 1989. Kyo-Dophilus use in the reduction
of Candida albicans symptoms. Chiron Consultants Inc. Calgary,
Canada.

Write a Review

Helpful Customer Reviews